DAMORA THERAPEUTICS, INC. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 83 rows, 83 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-02-09: Reporting owner Bruno Julianne; Form 4; Security Series C Preferred Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-02-09: Reporting owner Fairmount Healthcare Fund II L.P. | Harwin Peter Evan | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Kiselak Tomas; Form 4; Security Series C Preferred Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-02-09: Reporting owner Fairmount Healthcare Fund II L.P. | Harwin Peter Evan | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Kiselak Tomas; Form 4; Security Series C Preferred Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2025-11-17: Reporting owner Harwin Peter Evan | Kiselak Tomas | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Fairmount Healthcare Fund II L.P.; Form 3; Security Series B Preferred Stock; Transaction Holding.
DMRA insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-02-09 | Bruno Julianne Director | 4 | Series C Preferred Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −129 0 owned after | $0.00 | $24.00 | 2026-02-12 |
| 2026-02-09 | Fairmount Healthcare Fund II L.P. | Harwin Peter Evan | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Kiselak Tomas 10% Owner | Director, 10% Owner | 10% Owner | Director, 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · By Fairmount Healthcare Fund II L.P. | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,809 1,148 owned after | $0.00 | $24.00 | 2026-02-12 |
| 2026-02-09 | Fairmount Healthcare Fund II L.P. | Harwin Peter Evan | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Kiselak Tomas 10% Owner | Director, 10% Owner | 10% Owner | Director, 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · By Fairmount Healthcare Co-Invest V L.P. | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,904 574 owned after | $0.00 | $24.00 | 2026-02-12 |
| 2025-11-17 holding as of filing | Harwin Peter Evan | Kiselak Tomas | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Fairmount Healthcare Fund II L.P. Director, 10% Owner | 10% Owner | 10% Owner | Director, 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · By Fairmount Healthcare Fund II L.P. | Holding | no price filed | 2025-11-17 | ||
| 2025-11-17 holding as of filing | Harwin Peter Evan | Kiselak Tomas | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Fairmount Healthcare Fund II L.P. Director, 10% Owner | 10% Owner | 10% Owner | Director, 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · By Fairmount Healthcare Fund II L.P. | Holding | no price filed | 2025-11-17 | ||
| 2025-11-17 holding as of filing | Harwin Peter Evan | Kiselak Tomas | Fairmount Healthcare Co-Invest V L.P. | Fairmount Funds Management LLC | Fairmount Healthcare Fund II L.P. Director, 10% Owner | 10% Owner | 10% Owner | Director, 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · By Fairmount Healthcare Co-Invest V L.P. | Holding | no price filed | 2025-11-17 | ||
| 2025-11-17 holding as of filing | Bruno Julianne Director | 3 | Series C Preferred Stock Derivative · Direct | Holding | no price filed | 2025-11-17 | ||
| 2020-11-02 | GOLDFISCHER CARL Director | 4 | Series C-3 Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −392,367 0 owned after | $0.00 | $375.00 | 2020-11-04 |
| 2020-11-02 | GOLDFISCHER CARL Director | 4 | Series C-3 Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −7,475 0 owned after | $0.00 | $375.00 | 2020-11-04 |
| 2020-11-02 | GOLDFISCHER CARL Director | 4 | Series D Preferred Stock Derivative · Direct · (m) | C Conversion of derivative security | −3,688 0 owned after | $0.00 | $375.00 | 2020-11-04 |
| 2020-11-02 | Pedersen Anders Officer (Chief Operating Officer) | 4 | Series C-1 Preferred Stock Derivative · Direct | C Conversion of derivative security | −1,441 0 owned after | $0.00 | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series C-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −291,999 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series C-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −116,800 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series C-4 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −272,533 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series C-4 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −109,013 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series C-5 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −77,866 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series C-5 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −31,147 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −148,395 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −59,350 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −73,773 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Munshi Amit Director | 4 | Series D Preferred Stock Derivative · Direct | C Conversion of derivative security | −1,844 0 owned after | $0.00 | $375.00 | 2020-11-04 |
| 2020-11-02 | Schambye Hans T. Director, Officer (Chief Executive Officer) | 4 | Series C-1 Preferred Stock Derivative · Direct | C Conversion of derivative security | −5,359 0 owned after | $0.00 | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series C-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −291,999 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series C-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −116,800 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series C-4 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −272,533 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series C-4 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −109,013 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series C-5 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −77,866 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series C-5 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −31,147 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −148,395 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −59,350 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Khuong Chau Quang Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −73,773 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Christgau Stephan Director | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −184,433 0 owned after | $0.00 | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES B-1 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −25,562 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES B-2 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −15,833 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES B-3 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −63,333 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES B-4 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −66,666 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES C-1 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −133,991 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES C-2 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −194,666 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES C-4 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −181,688 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES C-5 PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −51,911 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-11-02 | Novo Holdings A/S 10% Owner | 4 | SERIES D PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −98,930 0 owned after | no price filed | $375.00 | 2020-11-04 |
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series C-2 Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series C-2 Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series C-4 Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series C-4 Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series C-5 Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series C-5 Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | OrbiMed Genesis GP LLC | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Israel GP II, L.P. | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series C-2 Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series C-2 Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series C-4 Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series C-4 Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series C-5 Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series C-5 Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Khuong Chau Quang Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES B-1 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES B-2 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES B-3 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES B-4 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES C-1 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES C-2 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES C-4 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES C-5 PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES D PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | GOLDFISCHER CARL Director | 3 | Series C-3 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | GOLDFISCHER CARL Director | 3 | Series C-3 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | GOLDFISCHER CARL Director | 3 | Series D Preferred Stock Derivative · Direct · (m) | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Pedersen Anders Officer (Chief Operating Officer) | 3 | Series C-1 Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Christgau Stephan Director | 3 | Series D Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Schambye Hans T. Director, Officer (Chief Executive Officer) | 3 | Series C-1 Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-10-28 holding as of filing | Munshi Amit Director | 3 | Series D Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-28 | ||
| 2020-09-25 | GOLDFISCHER CARL Director | 4 | Series D Preferred Stock Derivative · Direct · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,688 3,688 owned after | $27.11 | 2020-11-04 | |
| 2020-09-25 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −148,395 148,395 owned after | $27.11 | 2020-11-04 | |
| 2020-09-25 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −59,350 59,350 owned after | $27.11 | 2020-11-04 | |
| 2020-09-25 | OrbiMed Israel GP II, L.P. | OrbiMed Advisors Israel II Ltd | ORBIMED ADVISORS LLC | OrbiMed Genesis GP LLC | OrbiMed Capital GP VII LLC Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −73,773 73,773 owned after | $27.11 | 2020-11-04 | |
| 2020-09-25 | Munshi Amit Director | 4 | Series D Preferred Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,844 1,844 owned after | $27.11 | 2020-11-04 | |
| 2020-09-25 | Khuong Chau Quang Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −148,395 148,395 owned after | $27.11 | 2020-11-04 | |
| 2020-09-25 | Khuong Chau Quang Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −59,350 59,350 owned after | $27.11 | 2020-11-04 | |
| 2020-09-25 | Khuong Chau Quang Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −73,773 73,773 owned after | $27.11 | 2020-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |